Suppr超能文献

肝癌多药耐药单克隆细胞系HepG2/mdr1的建立。

Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.

作者信息

Chen Yong-Bing, Yan Mao-Lin, Gong Jian-Ping, Xia Ren-Pin, Liu Li-Xin, Li Ning, Lu Shi-Chun, Zhang Jing-Guang, Zeng Dao-Bing, Xie Jian-Guo, Yang Jia-Yin, Yan Lü-Nan

机构信息

Department of General Surgery, Second Hospital, Chongqing University of Medical Sciences, Chongqing, China.

出版信息

Chin Med J (Engl). 2007 Apr 20;120(8):703-7.

Abstract

BACKGROUND

The multidrug resistance (MDR) associated with the expression of the mdr1 gene and its product P-glycoprotein is a major factor in the prognosis of hepatocellular carcinoma cell (HCC) patients treated with chemotherapy. Our study was to establish a stable HCC MDR cell line where a de novo acquisition of multidrug resistance specifically related to overexpression of a transgenic mdr1.

METHODS

The 4.5-kb mdr1 cDNA obtained from the plasmid pHaMDR1-1 was cloned into the PCI-neo mammalian expression vector, later was transferred by liposome to human hepatocarcinoma cell line HepG2. Then the transfected HepG2 cells resisting G418 were clustered and cultured and the specific fragment of mdr1 cDNA, mRNA and the P-glycoprotein (Pgp) in these HepG2 cells were detected by PCR, RT-PCR and flow cytometry, respectively. The accumulation of the daunorubicin was determinated by flow cytometry simultaneously. The nude mice model of grafting tumour was established by injecting subcutaneously HepG2/mdr1 cells in the right axilla. When the tumour diameter reached 5 mm, adriamycin was injected into peritoneal cavity. The size and growth inhibition of tumour were evaluated.

RESULTS

The mdr1 expression vector was constructed successfully and the MDR HCC line HepG2/mdr1 developed. The PCR analysis showed that the specific fragment of mdr1 cDNA in HepG2/mdr1 cells, but not in the control group HepG2 cells. Furthermore, the content of the specific fragment of mdr1 mRNA and Pgp expression in HepG2/mdr1 cells were (59.7 +/- 7.9)% and (12.28 +/- 2.09)%, respectively, compared with (16.9 +/- 3.2)% and (3.07 +/- 1.06)% in HepG2 cells. In the nude mice HCC model, the tumour genes of both groups were identified. After ADM therapy, the mean size of HepG2 cell tumours was significantly smaller than HepG2/mdr1 cell tumours.

CONCLUSION

The approach using the transfer of mdr1 cDNA may be applicable to the development of MDR hepatocarcinoma cell line, whose MDR mechanism is known. This would provide the experimental basis of MDR research.

摘要

背景

与mdr1基因及其产物P-糖蛋白表达相关的多药耐药性是接受化疗的肝细胞癌(HCC)患者预后的主要因素。我们的研究旨在建立一种稳定的HCC多药耐药细胞系,该细胞系通过转基因mdr1的过表达从头获得多药耐药性。

方法

从质粒pHaMDR1-1中获得的4.5kb mdr1 cDNA克隆到PCI-neo哺乳动物表达载体中,随后通过脂质体将其转染到人肝癌细胞系HepG2中。然后对抵抗G418的转染HepG2细胞进行集落化培养,并分别通过PCR、RT-PCR和流式细胞术检测这些HepG2细胞中mdr1 cDNA、mRNA的特异性片段以及P-糖蛋白(Pgp)。同时通过流式细胞术测定柔红霉素的蓄积情况。通过将HepG2/mdr1细胞皮下注射到右腋窝建立裸鼠移植瘤模型。当肿瘤直径达到5mm时,向腹腔内注射阿霉素。评估肿瘤的大小和生长抑制情况。

结果

成功构建了mdr1表达载体并建立了多药耐药HCC细胞系HepG2/mdr1。PCR分析显示,mdr1 cDNA的特异性片段存在于HepG2/mdr1细胞中,而对照组HepG2细胞中未检测到。此外,HepG2/mdr1细胞中mdr1 mRNA特异性片段的含量和Pgp表达分别为(59.7±7.9)%和(12.28±2.09)%,而HepG2细胞中分别为(16.9±3.2)%和(3.07±1.06)%。在裸鼠HCC模型中,鉴定了两组的肿瘤基因。阿霉素治疗后,HepG2细胞肿瘤的平均大小明显小于HepG2/mdr1细胞肿瘤。

结论

使用mdr1 cDNA转染的方法可能适用于建立多药耐药机制明确的肝癌多药耐药细胞系。这将为多药耐药研究提供实验依据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验